Compare Nuscale Power Corporation (SMR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Nuscale Power Corporation trades at $9.51 (market cap $4.06B), while Vertex Pharmaceuticals Incorporated trades at $529.22 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 33.1× Nuscale Power Corporation's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| SMR | VRTX | |
|---|---|---|
Market Cap | $4.06B | $134.25B |
Sector | Utilities | Health |
52-Week High | $53.43 | $529.65 |
52-Week Low | $7.59 | $376.62 |
Enterprise Value | $2.99B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMR stock trades at $9.55, up 4.03% today, with a bullish technical signal from moving averages. The company reported a net loss of $355.79M on $31.48M revenue in 2025, with negative profit margins. Recent news highlights regulatory progress for its small modular reactor technology and potential from AI data center power demand.
Outlook hinges on commercial deployment success; high risk from persistent losses and execution challenges, but Wall Street consensus price target of $10.50 suggests moderate upside. Investor sentiment is divided, with 50% of analysts rating Buy amid significant financial volatility.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
